Microbial Cell-free Metagenomic Sequencing for Infections

(OPTIMUM Trial)

This trial tests whether the Karius Spectrum™ test, a metagenomic plasma-based test, can diagnose infections more quickly in people with weakened immune systems. Participants will provide a blood sample; some will receive results from the new test alongside regular medical tests, while others will only undergo the regular tests. The trial aims to determine if this blood test speeds up infection diagnosis and treatment. Ideal candidates for this trial include individuals with conditions such as organ transplant, cancer, or HIV who suspect an infection requiring diagnosis. As an unphased study, this trial offers a unique opportunity to contribute to innovative research that could enhance infection diagnosis for many patients in the future.

The trial information does not specify whether you need to stop taking your current medications. It seems likely that you can continue your medications, especially since the trial involves a one-time blood sample and focuses on adding a new test to usual care.

Research has shown that the Karius Spectrum test can detect over 1,000 different germs, including fungi, bacteria, and viruses, from just a blood sample. This method, called metagenomic sequencing, is quick and accurate. In terms of safety, participants in studies have generally tolerated the test well, as it requires only a single blood draw. No major issues have been directly linked to the test so far. This suggests the test is safe for humans, but discussing any concerns with a doctor before joining a trial is always advisable.¹²³⁴⁵

Researchers are excited about the metagenomic plasma-based test because it offers a unique approach to identifying infections. Unlike traditional methods that often rely on culturing pathogens, which can be time-consuming and sometimes ineffective for certain microbes, this test uses metagenomic sequencing to detect microbial DNA directly from plasma samples. This means it can potentially identify a wider range of pathogens faster and with greater accuracy. The ability to quickly determine the cause of an infection could lead to more targeted treatments and better patient outcomes.

Research has shown that the Karius Spectrum test can quickly and accurately identify over 1,000 different germs, including fungi, bacteria, and viruses, using advanced DNA sequencing from a blood sample. In real-world use, this test improved patient outcomes in about 57% of cases by enabling doctors to diagnose infections faster and initiate targeted treatments sooner. For more than half of the patients, the test either confirmed an infection or ruled it out, leading to better treatment decisions. In this trial, participants in the interventional arm will receive Karius Spectrum test results, which have demonstrated promise in speeding up infection diagnosis—crucial for timely and appropriate treatment, especially for patients with weakened immune systems. Participants in the control arm will not receive these test results.¹²³⁴⁶